ABCG2 and breast cancer: In conclusion, our study results further confirmed that 5-FU resistance may be mediated by BCRP expression in clinical breast cancer tissue specimens and may provide evidence supporting the role of BCRP as a mediator of 5-FU resistance, which may help optimize breast cancer clinical chemotherapy schemes in BCRP-positive specimens.